Enanta Pharmaceuticals
ENTA
194 hedge funds and large institutions have $1.49B invested in Enanta Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 77 increasing their positions, 56 reducing their positions, and 26 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 56
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less funds holding
Funds holding: 195 → 194 (-1)
1.95% less ownership
Funds ownership: 91.68% → 89.73% (-2%)
13% less capital invested
Capital invested by funds: $1.7B → $1.49B (-$213M)
63% less call options, than puts
Call options by funds: $4.51M | Put options by funds: $12.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$17.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.3M |
| 3 |
Janus Henderson Group
London,
|
+$6.33M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.12M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$22.3M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$15.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$9.23M |
| 4 |
Renaissance Technologies
New York
|
-$8.56M |
| 5 |
Millennium Management
New York
|
-$8.15M |
ENTA Hedge Fund Activity: Q2 2019 in Review
194 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2019, worth a combined $1.49B — down 13% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ENTA positions and 26 closed out — a net gain of 2 holders — while 77 added to existing stakes and 56 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $17.8M. The largest seller was OrbiMed, exiting entirely with an estimated $22.3M sold.
- 194 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2019, down from 195 in Q1 2019.
- Funds reported $1.49B of Enanta Pharmaceuticals stock for Q2 2019, down 13% quarter-over-quarter.
- 28 funds opened new Enanta Pharmaceuticals positions in Q2 2019 and 26 closed out, a net change of +2 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2019 was Nuveen, an estimated $17.8M added.
- The largest Enanta Pharmaceuticals seller in Q2 2019 was OrbiMed, an estimated $22.3M sold.
Based on aggregated 13F filings for Q2 2019.